Evidence map›Paper›PMID 30443683›Full record

ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Jesús Troya, Pablo Ryan, Rocío Montejano, Alfonso Cabello, Guillermo Cuevas, Mariano Matarranz, Irene Cañamares, Javier Solís, Luis Álvarez-Sala Walther

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jesús TroyaHospital Universitario Infanta Leonor, Madrid, Spain. jestrogar@hotmail.com.
Pablo RyanHospital Universitario Infanta Leonor, Madrid, Spain.
Rocío MontejanoHospital Universitario La Paz, Madrid, Spain.
Alfonso CabelloHospital Fundación Jiménez Díaz, Madrid, Spain.
Guillermo CuevasHospital Universitario Infanta Leonor, Madrid, Spain.
Mariano MatarranzHospital Universitario Infanta Leonor, Madrid, Spain.
Irene CañamaresHospital Universitario Infanta Leonor, Madrid, Spain.
Javier SolísHospital Universitario Infanta Leonor, Madrid, Spain.
Luis Álvarez-Sala WaltherSchool of Medicine, Universidad Complutense de Madrid, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

Indexed as

AbacavirAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDideoxynucleosidesDrug CombinationsDrug Resistance, ViralDrug SubstitutionHIV-1HIV InfectionsHumansLamivudineRaltegravir PotassiumRilpivirineTreatment OutcomeViral LoadAbacavirabacavir, lamivudine drug combinationAnti-HIV AgentsDideoxynucleosidesDrug CombinationsLamivudineRaltegravir PotassiumRilpivirineAbacavir/lamivudineEfficacyRaltegravirRilpivirineSafetySwitching

Identifiers

PMID30443683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.